Risk and timing of clinical events according to diabetic status of patients treated with everolimus‐eluting bioresorbable vascular scaffolds versus everolimus‐eluting stent: 2‐year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials

    loading  Checking for direct PDF access through Ovid


Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles